Jana Phillips, Honey E. East, Sarah E. French, Eugen Melcescu, Robert D. Hamilton, William C. Nicholas, Jonathan F. Fratkin, Andrew D. Parent, Gustavo Luzardo, Christian A. Koch
INTRODUCTION: Malignant prolactinoma is an exceedingly rare endocrine tumor and cannot be diagnosed on histological grounds alone. Similarly to other neuroendocrine tumors such as pheochromocytoma, the mitoses index, Ki-67, p53, and others are utilized in helping understand …
Mussa H. Almalki, Nora Nasser Aljoaib, Maha Jurais Alotaibi, Bayan Saloum Aldabas, Tayba Saleh Wahedi, Maswood M. Ahmad, Fahad Alshahrani
Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas …
Afif Nakhleh, Leonard Saiegh, Maria Reut, Mohammad Sheikh Ahmad, Irit Wirsansky Pearl, Carmela Shechner
OBJECTIVE: Cushing`s disease during pregnancy is associated with an increased risk for maternal and fetal complications. In recurrent Cushing`s disease following transsphenoidal surgery, and when re-operation is not feasible, medical treatment is usually considered. Cabergoline was found to be effective in reducing hypercortisolism in Cushing’s disease …
Labrini Papanastasiou, Stelios Fountoulakis, Theodora Pappa, Konstantinos Liberopoulos, Dimosthenis Malliopoulos, Athina Markou, George Piaditis
OBJECTIVE: Dopamine agonists (DA) are the treatment of choice in patients with macroprolactinomas. Brain and optic chiasm herniation are unusual complications following treatment with DA. REPORT: We present a case of a giant prolactinoma complicated by visual deterioration following cabergoline treatment …